Randomized trials comparing bone marrow transplantation with no transplantation or extra chemotherapy are required to overcome selection bias in survival analyses for acute myeloid leukemia.
Does bone marrow transplantation improve survival compared to conventional treatment in patients with acute myeloid leukaemia?
The text highlights the necessity of randomized controlled trials to overcome selection bias when evaluating the survival benefits of bone marrow transplantation in acute myeloid leukemia.
Research Council (MRC) 10 trial, children who had been tissue-typed and achieved CR have been used There are other methods of survival analysis available, which take into account time to transplant, age and other prognostic factors. They cannot, however, overcome the problem of selection bias: patients selected for BMT are likely to have a better (or worse) prognosis than patients who are treated conventionally. The only truly satisfactory way of assessing the value of BMT is to conduct randomized trials comparing BMT with no BMT -or with extra chemotherapy
Creutzig et al. (Thu,) conducted a review in Acute myeloid leukaemia. Bone marrow transplantation (BMT) vs. No BMT or extra chemotherapy was evaluated on Survival. Randomized trials comparing bone marrow transplantation with no transplantation or extra chemotherapy are required to overcome selection bias in survival analyses for acute myeloid leukemia.